✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
VIP peptide — short for vasoactive intestinal peptide — is a 28-amino-acid neuropeptide that researchers study for its powerful vasodilatory, bronchodilatory, and anti-inflammatory signalling. Unlike many compounds marketed under “peptide” branding, the VIP peptide genuinely is a peptide, occurring naturally throughout the nervous, respiratory, cardiovascular, and immune systems. This guide explains what VIP is, how it acts through VPAC receptors, what early studies suggest about its benefits, the route and dosage context seen in research, the side effects tied to its vasoactive nature, and how it compares with other anti-inflammatory peptides. Everything here is educational; VIP is not a licensed medicine in this form.
Key Takeaways
- VIP peptide is a naturally occurring 28-amino-acid neuropeptide that signals through VPAC1 and VPAC2 G-protein-coupled receptors.
- Its core actions are vasodilation, bronchodilation, smooth-muscle relaxation, and broad anti-inflammatory and immune-modulatory effects.
- Research contexts include pulmonary arterial hypertension, sarcoidosis, and acute respiratory distress — the synthetic analogue aviptadil was studied for respiratory failure.
- Intranasal VIP is widely discussed within CIRS (mould-illness) protocols, but that use is observational and not FDA-approved.
- VIP peptide side effects largely stem from vasodilation: flushing, hypotension, and diarrhoea.
- VIP is supplied for research use only and is not a licensed medicine in this form.
Medically reviewed by the MedsBase Editorial Team · Last updated: 24 May 2026 · For research and educational use only.
On This Page
- What Is VIP Peptide? (Vasoactive Intestinal Peptide)
- How Does VIP Peptide Work? (VPAC Receptors)
- Key Benefits & Uses of VIP Peptide
- VIP Peptide Side Effects, Safety & Dosage
- What Does the Research Say?
- VIP Peptide vs Alternatives
- How to Use VIP Peptide — Practical Guidance
- Frequently Asked Questions
- The Bottom Line
What Is VIP Peptide? (Vasoactive Intestinal Peptide)
VIP peptide, or vasoactive intestinal peptide, is a naturally occurring 28-amino-acid neuropeptide that relaxes blood vessels and airway muscle while dampening inflammation. It belongs to the secretin–glucagon family and acts as both a neurotransmitter and a signalling hormone across the body.
Vasoactive intestinal peptide was first isolated from the small intestine, which gave the molecule its name, but scientists soon found it throughout the central and peripheral nervous systems, the lungs, the heart, and immune tissues. It is released from nerve terminals and certain immune cells, then acts locally on nearby receptors. Because it is broken down quickly in the bloodstream, the body uses VIP as a short-range messenger rather than a long-lasting circulating hormone.
The molecule sits within a peptide family that includes PACAP (pituitary adenylate cyclase-activating polypeptide), with which it shares much of its receptor biology. In the research-grade peptide market, VIP is stocked as a lyophilised powder for laboratory study. You can see how it sits alongside other research compounds in the wider research peptides catalogue. The U.S. National Library of Medicine maintains an overview of related neuropeptide signalling for those who want primary-source background (NIH PMC).
How Does VIP Peptide Work? (VPAC Receptors)
VIP peptide works by binding two G-protein-coupled receptors named VPAC1 and VPAC2. When VIP docks onto a VPAC receptor, the receptor activates an enzyme called adenylate cyclase, which raises intracellular cyclic AMP. That second-messenger surge relaxes smooth muscle, widens blood vessels, opens airways, and shifts immune cells toward a calmer, anti-inflammatory state. The two receptor subtypes are distributed differently: VPAC1 is common in the lungs, liver, and gut, while VPAC2 is concentrated in vascular smooth muscle, immune tissue, and the brain’s master clock.
Research Spotlight
Reviews of VIP immunology describe how the peptide pushes immune cells away from pro-inflammatory signalling and toward regulatory, tolerance-promoting behaviour. Researchers have proposed this VPAC-receptor mechanism as a reason VIP is being explored in inflammatory and autoimmune research models — though human evidence remains early and the VIP peptide is not an approved therapy.
This VPAC receptor mechanism explains why a single molecule can touch so many systems at once. In the lungs it both dilates airways and relaxes the pulmonary blood vessels. In the immune system it tempers cytokine output. And in the suprachiasmatic nucleus — the brain’s circadian pacemaker — VPAC2 signalling helps synchronise the daily clock. The breadth of this signalling is exactly what makes VIP peptide interesting to researchers, and also why effects can be hard to isolate.
Infographic text: VIP peptide → binds VPAC1 + VPAC2 receptors → activates adenylate cyclase → raises cyclic AMP → results in (1) vasodilation, (2) bronchodilation, (3) anti-inflammatory immune shift, (4) circadian clock synchronisation.
Key Benefits & Uses of VIP Peptide
The reported VIP peptide benefits map directly onto its biology. Below are the four research areas where vasoactive intestinal peptide is most discussed. Each is described in research terms, because none represents an approved human treatment in this form.
Respiratory & Pulmonary Research
Because VIP relaxes both airway muscle and pulmonary blood vessels, it has long been studied in pulmonary arterial hypertension and obstructive airway models. Early work led by Said and colleagues suggested VIP could lower elevated pulmonary pressures, and the synthetic analogue aviptadil was later studied in respiratory-failure trials. Research suggests the peptide’s dual bronchodilator and vasodilator action is the basis for this interest, though results have been mixed.
Anti-Inflammatory & Immune Modulation
One of the most-cited VIP peptide benefits is immune modulation. Laboratory studies indicate VIP shifts immune cells toward regulatory, tolerance-promoting behaviour and reduces pro-inflammatory cytokines. This is why VIP appears in sarcoidosis research and in autoimmune-model literature. For readers interested in immune-active peptides more broadly, our LL-37 cathelicidin guide covers a different but complementary immune mechanism.
CIRS & Intranasal VIP (Observational Use)
Intranasal VIP is widely discussed within chronic inflammatory response syndrome (CIRS), also called mould illness, through the protocol associated with Dr Ritchie Shoemaker. Proponents report improvements in inflammatory markers and quality of life when intranasal VIP is used late in that protocol. It is essential to be clear: this CIRS use is observational, not validated by controlled trials, and not FDA-approved. Anyone exploring intranasal VIP should treat the available evidence as preliminary.
Circadian & Vascular Signalling
Through VPAC2 receptors in the suprachiasmatic nucleus, VIP helps keep the body’s circadian clock synchronised, and animal studies link disrupted VIP signalling to fragmented sleep–wake rhythms. Its vasodilatory role also extends to coronary and systemic vessels. These overlapping vascular and circadian roles are why VIP sometimes appears in longevity-oriented discussions — see our best longevity peptides overview for related compounds.
Who Is This Research Most Relevant To?
- Researchers and clinicians studying pulmonary vascular and airway biology.
- Immunology labs investigating anti-inflammatory and tolerance-promoting peptides.
- Those following the scientific literature on aviptadil and respiratory failure.
- People researching CIRS protocols who want an evidence-honest summary of intranasal VIP.
VIP Peptide Side Effects, Safety & Dosage
The most common VIP peptide side effects follow logically from its vasoactive nature: by relaxing blood vessels it can lower blood pressure and cause flushing, and by relaxing gut smooth muscle it can cause loose stools. The table below summarises the effects most often described in research settings. These are reported observations, not a complete safety profile, because VIP is not a licensed medicine in this form.
| Side Effect | Frequency | Severity |
|---|---|---|
| Facial flushing / warmth | Common | Mild |
| Low blood pressure (hypotension) | Common | Mild–moderate |
| Diarrhoea / loose stools | Common | Mild |
| Lightheadedness on standing | Occasional | Mild |
| Nasal irritation (intranasal route) | Occasional | Mild |
| Rapid heartbeat (reflex tachycardia) | Uncommon | Moderate |
On VIP peptide dosage: there is no established human dose, and figures quoted online come from research protocols rather than approved labelling. In the literature, VIP is most often delivered intranasally — the route used in the CIRS-protocol discussion — and has also been given by intravenous infusion in pulmonary-hypertension and respiratory studies, where slow titration is used specifically to limit the hypotension and flushing seen above. Because the peptide is degraded rapidly, research dosing is frequent or continuous rather than once-daily. None of this constitutes dosing advice; VIP is supplied for laboratory research only.
What Does the Research Say About VIP Peptide?
VIP has decades of laboratory and early-clinical study behind it, but the evidence base remains preliminary and the findings are mixed. The table below highlights representative research themes. Where an exact identifier is not certain, the source is described generally rather than fabricated.
| Study / Theme | Year | Finding (qualified) | Source |
|---|---|---|---|
| Said et al. — VIP & pulmonary hypertension | 2000s | Early work suggested inhaled VIP may lower pulmonary artery pressure in small studies. | PubMed |
| Aviptadil (synthetic VIP) in respiratory failure | 2020–2022 | Aviptadil was studied for acute respiratory distress and COVID-19 respiratory failure; trial results were mixed and it is not approved for this use. | ClinicalTrials.gov |
| PMC reviews — VIP immunology | 2010s–2020s | Reviews describe VIP as a regulator that promotes immune tolerance and dampens inflammation in laboratory models. | NIH PMC |
| VIP in sarcoidosis | 2010s | Small studies explored inhaled VIP as an anti-inflammatory approach in sarcoidosis; evidence is early. | PubMed |
Infographic text: Research themes for VIP peptide — pulmonary hypertension (early, small studies) → aviptadil ARDS/COVID-19 trials (mixed, not approved) → immune-tolerance reviews (preclinical) → sarcoidosis (early). Across all, the honest summary is: promising mechanism, immature human evidence.
The most prominent clinical thread is aviptadil. As a synthetic version of vasoactive intestinal peptide, aviptadil was advanced into trials for respiratory failure, and those studies are documented in public registries. Importantly, the trial programme did not result in broad regulatory approval, so aviptadil should be understood as investigational. You can read the National Heart, Lung, and Blood Institute’s broader research context on respiratory therapeutics at the NHLBI.
VIP Peptide vs Alternatives (Other Anti-Inflammatory Peptides)
VIP is one of several peptides studied for anti-inflammatory or regenerative signalling. The comparison below is for research orientation only and does not imply any of these compounds is a treatment.
| Peptide | Primary research angle | Typical research route | Distinguishing feature |
|---|---|---|---|
| VIP | Vasodilation, bronchodilation, immune tolerance | Intranasal / IV infusion | VPAC1/VPAC2 GPCR signalling; circadian role |
| LL-37 (cathelicidin) | Antimicrobial, wound-healing, immune | Subcutaneous | Direct antimicrobial action + vitamin-D axis |
| BPC-157 | Tissue repair, gut healing | Subcutaneous / oral | Angiogenesis and gut-focused repair signalling |
| Thymosin Beta-4 (TB-500) | Repair, anti-inflammatory | Subcutaneous | Actin-binding; cell migration in repair |
The clearest distinction is that VIP is a receptor-targeted vasoactive and immune signalling peptide, whereas LL-37, BPC-157, and TB-500 are studied mainly for tissue repair and host defence. That makes VIP peptide a complement to, rather than a substitute for, those compounds in a research context.
How to Use VIP Peptide — Practical Guidance
In a laboratory setting, VIP peptide arrives as a lyophilised (freeze-dried) powder that must be reconstituted with a suitable diluent before study. Because VIP is fragile and degrades quickly, careful handling matters: gentle reconstitution without vigorous shaking, refrigerated storage of the reconstituted solution, and short in-use windows are all standard practice. Our step-by-step peptide reconstitution guide walks through bacteriostatic-water ratios and sterile technique.
Research handling of VIP most commonly uses the intranasal route discussed earlier, while clinical study has used controlled intravenous infusion. Whichever route a protocol specifies, slow administration is favoured to limit the flushing and hypotension that follow rapid vasodilation. If you are sourcing material for study, the research-grade VIP (Vasoactive Intestinal Peptide) product page lists vial specifications, and the wider peptides category carries the bacteriostatic water and supplies needed for reconstitution. Remember: this material is for laboratory research only and is not intended for human use.
Frequently Asked Questions
What is VIP peptide used for?
In research, VIP peptide is used to study vasodilation, airway relaxation, and anti-inflammatory immune modulation. It appears in literature on pulmonary arterial hypertension, sarcoidosis, acute respiratory distress, and chronic inflammatory response syndrome. None of these represents an approved use in this form; VIP is supplied for laboratory research only and is not a licensed medicine.
Is VIP peptide safe?
VIP is not approved as a medicine, so a full human safety profile has not been established. The side effects most often reported in research follow from its vasodilatory action — flushing, low blood pressure, lightheadedness, and diarrhoea. Because of these vasoactive effects, slow administration is used in studies. Treat all VIP material as research-only and never self-administer; consult a qualified clinician for any health concern.
What is intranasal VIP?
Intranasal VIP refers to delivering vasoactive intestinal peptide as a nasal spray, the route featured in the CIRS (mould-illness) protocol associated with Dr Shoemaker. Proponents report improvements in inflammatory markers, but this use is observational and has not been confirmed by controlled trials. It is not an FDA-approved therapy, and the intranasal evidence base remains preliminary.
What is the difference between VIP peptide and aviptadil?
Aviptadil is a synthetic, pharmaceutical-grade version of vasoactive intestinal peptide, sometimes labelled RLF-100. It was advanced into clinical trials for respiratory failure, including COVID-19, whereas research-grade VIP peptide is supplied for laboratory study. They share the same core molecule, but aviptadil refers specifically to the investigational drug-development programme, which did not result in broad approval.
Can VIP peptide help with CIRS or mould illness?
Within CIRS protocols, intranasal VIP is used late in the sequence and some practitioners report symptom and biomarker improvement. However, this is observational practice, not evidence from controlled clinical trials, and it is not FDA-approved. Anyone considering it should work with a knowledgeable clinician and understand that the supporting evidence is preliminary rather than definitive.
How does VIP peptide work in the body?
VIP peptide binds VPAC1 and VPAC2 receptors, which raise cyclic AMP inside cells. That signalling relaxes blood vessels and airway muscle, calms inflammatory immune cells, and — through VPAC2 receptors in the brain’s master clock — helps regulate circadian rhythm. This VPAC receptor mechanism explains why a single peptide influences respiratory, vascular, immune, and sleep-related systems.
What is a typical VIP peptide dosage?
There is no established or approved VIP peptide dosage. Figures circulating online come from research protocols, not labelling. In studies the peptide is usually given intranasally or by slow intravenous infusion, with titration to limit hypotension and flushing. Because the molecule degrades quickly, dosing tends to be frequent. None of this is dosing guidance — VIP is for research use only.
Where does VIP come from naturally?
Vasoactive intestinal peptide was first isolated from the small intestine, but the body produces it throughout the nervous system, lungs, heart, and immune tissue. It acts as a short-range neurotransmitter and signalling molecule, released locally from nerve endings and certain immune cells, then rapidly broken down — which is why the natural peptide works close to where it is released.
The Bottom Line
The VIP peptide is a genuinely fascinating molecule: a single 28-amino-acid neuropeptide that relaxes vessels, opens airways, calms inflammation, and helps set the body’s clock through VPAC1 and VPAC2 receptors. Research suggests real promise in pulmonary, immune, and inflammatory biology, and the aviptadil trials show how seriously the molecule has been studied — yet the human evidence remains early and mixed, and intranasal VIP for CIRS stays observational rather than proven. If you are sourcing material for legitimate laboratory study, explore the research-grade VIP product page and the wider peptides range, and always pair it with proper handling and qualified guidance.
Medical Disclaimer
This article is for educational and research purposes only and is not medical advice. VIP (vasoactive intestinal peptide) is supplied for laboratory research use and is not a licensed medicine or an approved treatment for any condition in this form. Statements about benefits, dosage, and routes describe research observations, not recommendations. Do not self-administer research peptides. Always consult a qualified healthcare professional before making any health decision.
Written and medically reviewed by the MedsBase Editorial Team in line with our editorial policy. Last updated: 24 May 2026.
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.